Biotech M&A Primed For 2006: Vertex Pharmaceuticals Could Lead Off Banner Year Of Biotech Buys
You may also be interested in...
Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks
Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks
Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA
Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab